IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

		N.
Ann	diaa	ints:
\sim	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	11113

Philippe L. Durette, et al.

Serial No. 09/086,327 Filed: May 28, 1998

For: HETEROCYCLIC AMIDE COMPOUNDS AS CELL

ADHESION INHIBITORS

OCT 2 5 2004

Art Unit: 1653

Examiner: David Lukton

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Muli Date 10/20/04

Computer generated form "IDS Letter" (IDS Folder), Merck & Co., Inc., 08/11/2003

SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED AP	PLICATION
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE
		-

If th	is is inconvenient, additional copies will be submitted upon request.
(6. In accordance with 37 C.F.R. 1.97, (check one)
	the attached information is filed within three months of the filing date of the captioned case.
	the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
	the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
\checkmark	the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
	the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.
	Respectfully submitted,

By: Mollie M. Yang

Attorney For Applicant(s)

Reg. No. 32,718

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-6343

10/21/21

	1			Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE
Sı	ubstitute for form 1449A/PTO	SUPPLEMENTAL		COMPLETE IF KNOWN
I	NFORMATION :		Application Number	09/086,327
	STATEMENT BY	TOT P E	Filing Date	May 28, 1998
3	DIAIEWIENI BY	APPLICANE	First Named Inventor	Philippe L. Durette
	(use as many sheets	OCT 2 5 ZUVA	Group Art Unit	1653
	(use as many sheets	necessary)	Examiner Name	David Lukton
Sheet	1	of 2	Attorney Docket Number	19965Y

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY
		4,350,698		John G. Gleason, et al.	09/21/1982

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Office	Foreign Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		EP	0 696 593 A2		Leftheris, et al.	02/14/1996	
		wo	96/40641		Ila Sircar, et al.	12/19/1996	
		ī			Dete		

Examiner Date Considered			
Signature	Examiner Signature	Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Su	bstitute for form 1449B/PTO	CIIDI	PLEMENTAL	(COMPLETE IF KNOWN
	NFORMATION			Application Number	09/086,327
G	TATEMENT BY	AD	PE	Filing Date	May 28, 1998
3	IAIEMENIDI	AP	PIJCANI	First Named Inventor	Philippe L. Durette
		ļ	OCT 25 2004	Group Art Unit	1653
	(use as many sheets	as n	1882 - 10E.	Examiner Name	David Lukton
Sheet	2	of	2	Attorney Docket Number	19965Y

Examinar No. Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.	NON PATENT LITERATURE DOCUMENTS					
Gerardo Byk, et al., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, Vol. 5, No. 22, pp. 2677-2682, (1995)	Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
			Gerardo Byk, et al., <u>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS</u> , Vol. 5, No. 22, pp. 2677-2682, (1995)			
		-				
	_					

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.